logo-loader
AIM:THAT

Thalia Therapeutics PLC

Receive alerts
Market:
AIM
Price
0.60 GBX
Day Change
4.35%
Market Cap:
£10.65 m
52 weeks high
0.95
52 weeks low
0.40

In brief

Thalia Therapeutics is a biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease. 

The company is focused on unlocking the full therapeutic potential of RNA by overcoming the fundamental challenges of delivery, enabling targeted, scalable and clinically meaningful medicines for patients with significant unmet medical needs.

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Firms across the coronavirus treatment chain see share prices surge

Companies involved in diagnostics, drug development and medical equipment provision have all seen strong stock price rises as the world grapples with the pandemic

on 30/3/20